StreetInsider.com News Articles

Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920905.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920905.html

Form 4 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26865885.html

Form 4 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26865885.html

Form 3 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26861522.html

Form 3 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26861522.html

Form 8-K iBio, Inc. For: Jul 31

Tue, 04 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260804/26861427.html

Form 8-K iBio, Inc. For: Jul 31

Tue, 04 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260804/26861427.html

iBio names endocrinologist Molly Carr as chief medical officer

Tue, 04 Aug 2026 07:00:40 -0400

iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company, has appointed Molly Carr, M.D., as chief medical officer, according to a company statement. Dr. Carr will oversee global clinical strategy, medical affairs, and regulatory initiatives.

Dr. Carr brings more than 30 years of experience in endocrinology and metabolic disease across clinical, academic, and biopharmaceutical roles. She previously held positions at Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University, and the University of Washington. Most recently, she served as clinical head and associate vice president of Lilly's Insulin and Glucagon Franchise, where she led the Phase 3 program for efsitora, a

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

Tue, 04 Aug 2026 07:00:00 -0400

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company’s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.

Prior to

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

Tue, 04 Aug 2026 07:00:00 -0400

Prior to

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

Tue, 04 Aug 2026 07:00:00 -0400

Prior to

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

Tue, 04 Aug 2026 07:00:00 -0400

Prior to

Form 8-K iBio, Inc. For: Jul 17

Fri, 17 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26784417.html

Form 8-K iBio, Inc. For: Jul 17

Fri, 17 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26784417.html

Form 8-K iBio, Inc. For: Jul 01

Wed, 01 Jul 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260701/26716850.html

Form 8-K iBio, Inc. For: Jul 01

Wed, 01 Jul 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260701/26716850.html

iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs

Wed, 01 Jul 2026 07:02:23 -0400

iBio, Inc. (NASDAQ: IBIO) announced preclinical data from an obese non-human primate study evaluating IBIO-610, an Activin E antibody candidate, according to a press release from the clinical-stage biotechnology company.

In the study, a single dose of IBIO-610 reduced active Activin E levels in all treated animals through eight weeks. Active Activin E was reduced by 98% at week four and 97% at week eight compared with baseline, with levels falling below the limits of the assay at both time points.

In obese non-human primates receiving IBIO-610 in combination with semaglutide, the combination produced greater visceral and total fat loss while reducing

iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs

Wed, 01 Jul 2026 07:02:23 -0400

In obese non-human primates receiving IBIO-610 in combination with semaglutide, the combination produced greater visceral and total fat loss while reducing

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced new preclinical data from its

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.

The analyst comments "We initiate coverage of iBio (IBIO) with an Outperform rating and $5 target price. IBio using its proprietary AI-integrated platform to is developing next-generation antibody therapies for challenging targets; its first antibody (IBIO-600, myostatin) recently entered the clinic with two more INDs expected in the next 12 months. We see a compelling valuation and an excellent riskreward for investors as the company’s diverse set of potentially differentiated assets approach PoC in areas of high unmet need

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.